Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition

Area of Science:

• Immunology
• Vaccinology
• Viral Vector Technology

Background:

• Preexisting immunity can hinder viral vector vaccine efficacy.
• Neutralizing antibodies and cytotoxic T lymphocytes (CTLs) are considered primary immune effectors against vectors.

Purpose of the Study:

• To investigate the impact of vector-specific immunity on boosting responses against a model antigen (HPV E6E7).
• To determine the role of antibodies and CTLs in modulating prime-boost immunization efficacy with recombinant Semliki Forest virus (rSFV).

Main Methods:

• Utilized rSFV expressing HPV E6E7 antigen in mice.
• Assessed E6E7-specific CTL responses after homologous and heterologous prime-boost regimens.
• Investigated the effect of passively transferred SFV-neutralizing antibodies.
• Evaluated the impact of co-administering E7 protein during priming.

Main Results:

• Secondary E6E7-specific immune responses were not inhibited by vector-specific antibodies or CTLs.
• Antigen presence during prime immunization was crucial for boosting efficacy.
• Homologous boosting with rSFVeE6,7 induced robust E6E7-specific CTL responses and memory.
• Co-administration of E7 protein during priming with an irrelevant vector abolished inhibition by vector-specific immunity.

Conclusions:

• Vector-specific antibodies and CTL-mediated killing are not the primary barriers to effective viral vector prime-boost immunization.
• T-cell competition may play a significant role in regulating immune responses during prime-boost vaccination strategies.
• Optimizing antigen exposure during priming is critical for enhancing vaccine efficacy.